The topical issues of clinical pharmacology of clarithromycin

Authors

  • O. O. Yakovleva Vinnitsa National Medical University, Ukraine
  • A. B. Ilchenko Vinnitsa National Medical University, Ukraine

DOI:

https://doi.org/10.24959/nphj.15.2023

Keywords:

clarithromycin, indirect antibacterial effects, nonantibacterial effects immunomodulatory effect

Abstract

Recently, as evidenced by numerous publications and surveys on the topic, the interest in clarithromycin is not reduced. This drug has a wide range of the antibacterial activity, is able to penetrate into cells and create stable and high tissue concentration exceeding the level of the drug in the blood serum. However, in recent years, more attention is paid to the study of nonantibacterial effects of clarithromycin. In modern macrolides, in particular in clarithromycin, the anti-inflammatory, immunomodulatory and mucoregulatory properties have been found. The primary mechanism of the immunomodulatory action of macrolides today is considered to be their ability to affect NF-kB-and MAPK-dependent signaling pathways of cells. Under the effect of clarithromycin the decrease in the synthesis and/or secretion of pro-inflammatory (IL-1, -6, -8, tumour necrosis factor (TNF)) and the increase in the secretion of anti-inflammatory cytokines (IL-2, -4, -10) are observed. The effectiveness of the indirect antimicrobial action of clarithromycin is intensively studied in vitro and in vivo, and it further expands our understanding of the therapeutic possibilities of this drug.

Author Biographies

O. O. Yakovleva, Vinnitsa National Medical University

Заведующая кафедрой клинической фармации и клинической фармакологии

A. B. Ilchenko, Vinnitsa National Medical University

Аспирант кафедры клинической фармации и клинической фармакологии

References

Волосовец А.П., Кривопустов С.П. Макролиды в практике современной педиатрии. — К.: Четверта хвиля. - 2009. — 192 c.

Зузова А.П., Белькова Ю.А. // Фарматека. – 2007. - №17. – С22-28

Фещенко Ю.И., Яшина Л.А. // Здоров’я України. – 2008. -№16. – С. 42-43.

Aikaterini Spyridaki A., Antonopoulou A., Raftogiannis M. et al. // Antimicrobial Agents and Chemotherapy. – 2012. – Vol. 56. – P. 3819–3825.

Amado-Rodríguez L., González-López A., López-Alonso I. et al. // Respiratory Research. - 2013. - Vol .14. – P. 52-57.

Benerjee D., Honeybourne D., Khair O.A. // Treat Respir Med. - 2004. – Vol. 3. – P. 59–65.

Buyck J.M., Plésiat P., Traore H. Et al. // Clinical Infectious Diseases. - 2012. –Vol. 55(4). – P. 534–542.

Giamarellos-Bourboulis E. J., Peche J.-C., Routsi C. et al. // Clinical Infectious Diseases. - 2008. – Vol. 46. – P. 1157–1164.

Foroutana S.M., Shafaatib A., Zarghib A. et al. // Iranian Journal of Pharmaceutical Research. - 2013. – Vol. 12. – P. 65-69.

Hirata K., Nishizawa H., Suzuki T. et al. // J.Gastroenterol Hepatol. – 2010. - Vol. 25. - P. 75-79.

Kohyama T., Takizawa H., Yamauchi Y. et al. // Respir Med. - 2008. - Vol. 102(12). – P. 1769-1776.

Kozlov R.S., Sivaja O.V., Stratchounski L.S. 7-years monitoring of resistance of clinical S. Pneumoniae in Russia: results of prospective multicenter study (PEHASus) / // Proc 45th , Washington DC ICAAC. - 2005.

Larissa L., Pereira D.C., Paiva R.M. et al. // BMC Microbiology. - 2012. – Vol. 12. – P. 196-199.

Morita Y., Tomidaand J., KawamuraY. Responses of Pseudomonas aeruginosa to antimicrobials // Antimicrobials, Resistance and Chemotherapy. - 2014. – Vol. 4. – P. 422-428.

Nixon L.S., Boorman J., Papagiannis A.J. et al. // Respiratory Medicine. - 2007. – Vol. 101. – P. 2409-2415.

Restrepo M.I., Mortensen E.M., Waterer G.W. et al. // Eur Respir J. - 2009. - Vol. 33. – P. 153–159.

Shinahara W., Sawabuchi T., Takahashi E. et al. // PLoS ONE. – 2013. - Vol. 8(7). – P. 124-130.

Tagaya E., Kondo M., Tamaoki J. et al. // Chest. - 2002. – Vol. 122. – P. 213–218.

Tamaoki J. // Chest. - 2004. – Vol. 125. – P. 41–51.

Tanabe T., Kanoh S., Tsushima K. et al. // Am. J. Respir. Cell Mol. Biol. – 2011. - Vol. 45, № 5. - P. 1075–1083.

Walkey Allan J., Wiener R. S. // Chest. - 2012. – Vol. 5. – P. 141-143.

Wozniak D.J., Keyser R. // Chest. - 2004. – Vol. 125. – P. 62–69.

Downloads

Published

2015-09-11

Issue

No. 3(83) (2015)

Section

Experimental and Clinical Pharmacology

License

Copyright (c) 2015 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).